Erythropoietin protects against rhabdomyolysis-induced acute kidney injury by modulating macrophage polarization

Cell Death and Disease

Volumn 8, Issue 4, 2017, Pages

  Wang, Shuo ^a,b   Zhang, Chao ^a,b   Li, Jiawei ^a,b   Niyazi, Sidikejiang ^a,b   Zheng, Long ^a,b   Xu, Ming ^a,b   Rong, Ruiming ^a,b   Yang, Cheng ^a,b   Zhu, Tongyu ^a,b  

^a FUDAN UNIVERSITY   (China)

^b Shanghai Key Laboratory of Organ Transplantation   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; INTERLEUKIN 6; JANUS KINASE 2; KIDNEY INJURY MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 3; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; RECOMBINANT ERYTHROPOIETIN; STAT3 PROTEIN; STAT6 PROTEIN; TUMOR NECROSIS FACTOR; ERYTHROPOIETIN; JAK2 PROTEIN, MOUSE; STAT3 PROTEIN, MOUSE; STAT6 PROTEIN, MOUSE;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL POLARITY; CONTROLLED STUDY; DRUG MECHANISM; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; RHABDOMYOLYSIS; TREATMENT OUTCOME; ANIMAL; COMPLICATION; DRUG EFFECTS; IMMUNOLOGY; PATHOLOGY; SIGNAL TRANSDUCTION;

ACUTE KIDNEY INJURY; ANIMALS; ERYTHROPOIETIN; JANUS KINASE 2; MACROPHAGES; MICE; RHABDOMYOLYSIS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STAT6 TRANSCRIPTION FACTOR;

EID: 85028468529     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2017.104     Document Type: Article

References (62)

1. Huerta-Alardin AL, Varon J, Marik PE. Bench-to-bedside review: Rhabdomyolysis - an overview for clinicians. Crit Care 2005; 9:158-169.
2. Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med 2009; 361:62-72.
3. Bywaters EG, Beall D. Crush Injuries with Impairment of Renal Function. Br Med J 1941; 1: 427-432.
4. Vanholder R, Sever MS, Erek E, Lameire N. Rhabdomyolysis. J Am Soc Nephrol 2000; 11: 1553-1561.
5. Chatzizisis YS, Misirli G, Hatzitolios AI, Giannoglou GD. The syndrome of rhabdomyolysis: complications and treatment. Eur J Intern Med 2008; 19: 568-574.
6. Woodrow G, Brownjohn AM, Turney JH. The clinical and biochemical features of acute renal failure due to rhabdomyolysis. Ren Fail 1995; 17: 467-474.
7. de Meijer AR, Fikkers BG, de Keijzer MH, van Engelen BG, Drenth JP. Serum creatine kinase as predictor of clinical course in rhabdomyolysis: a 5-year intensive care survey. Intensive Care Med 2003; 29:1121-1125.
8. Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore) 2005; 84: 377-385.
9. Zhang L, Fu P, Wang L, Cai G, Zhang L, Chen D et al. The clinical features and outcome of crush patients with acute kidney injury after the Wenchuan earthquake: differences between elderly and younger adults. Injury 2012; 43:1470-1475.
10. Heyman SN, Rosen S, Rosenberger C. Animal models of renal dysfunction: acute kidney injury. Expert Opin Drug Discov 2009; 4: 629-641.
11. Paller MS Hemoglobin- and myoglobin-induced acute renal failure in rats: role of iron in nephrotoxicity. Am J Physiol 1988; 255: F539-F544.
12. Zager RA, Gamelin LM. Pathogenetic mechanisms in experimental hemoglobinuric acute renal failure. Am J Physiol 1989; 256: F446-F455.
13. Zager RA Combined mannitol and deferoxamine therapy for myohemoglobinuric renal injury and oxidant tubular stress. Mechanistic and therapeutic implications. J Clin Invest 1992; 90: 711-719.
14. Kim JH, Lee SS, Jung MH, Yeo HD, Kim HJ, Yang JI et al. N-acetylcysteine attenuates glycerol-induced acute kidney injury by regulating MAPKs and Bcl-2 family proteins. Nephrol Dial Transplant 2010; 25: 1435-1443.
15. Fahling M, Mathia S, Paliege A, Koesters R, Mrowka R, Peters H et al. Tubular von Hippel-Lindau knockout protects against rhabdomyolysis-induced AKI. J Am Soc Nephrol 2013; 24: 1806-1819.
16. Zarjou A, Bolisetty S, Joseph R, Traylor A, Apostolov EO, Arosio P et al. Proximal tubule H-ferritin mediates iron trafficking in acute kidney injury. J Clin Invest 2013; 123: 4423-4434.
17. Homsi E, Ribeiro-Alves MA, Lopes de Faria JB, Dias EP. Interleukin-6 stimulates tubular regeneration in rats with glycerol-induced acute renal failure. Nephron 2002; 92: 192-199.
18. Homsi E, Janino P, de Faria JB Role of caspases on cell death, inflammation, and cell cycle in glycerol-induced acute renal failure. Kidney Int 2006; 69: 1385-1392.
19. Homsi E, Janino P, Amano M, Saraiva Camara NO Endogenous hepatocyte growth factor attenuates inflammatory response in glycerol-induced acute kidney injury. Am J Nephrol 2009; 29: 283-291.
20. Geng Y, Zhang L, Fu B, Zhang J, Hong Q, Hu J et al. Mesenchymal stem cells ameliorate rhabdomyolysis-induced acute kidney injury via the activation of M2 macrophages. Stem Cell Res Ther 2014; 5: 80.
21. Belliere J, Casemayou A, Ducasse L, Zakaroff-Girard A, Martins F, Iacovoni JS et al. Specific macrophage subtypes influence the progression of rhabdomyolysis-induced kidney injury. J Am Soc Nephrol 2015; 26: 1363-1377.
22. Komada T, Usui F, Kawashima A, Kimura H, Karasawa T, Inoue Y et al. Role of NLRP3 Inflammasomes for Rhabdomyolysis-induced Acute Kidney Injury. Sci Rep 2015; 5: 10901.
23. Nishida K, Watanabe H, Ogaki S, Kodama A, Tanaka R, Imafuku T et al. Renoprotective effect of long acting thioredoxin by modulating oxidative stress and macrophage migration inhibitory factor against rhabdomyolysis-associated acute kidney injury. Sci Rep 2015; 5: 14471.
24. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005; 293: 90-95.
25. Ghezzi P, Bernaudin M, Bianchi R, Blomgren K, Brines M, Campana W et al. Erythropoietin: not just about erythropoiesis. Lancet 2010; 375: 2142.
26. Nairz M, Schroll A, Moschen AR, Sonnweber T, Theurl M, Theurl I et al. Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-kappaB-inducible immune pathways. Immunity 2011; 34: 61-74.
27. Cravedi P, Manrique J, Hanlon KE, Reid-Adam J, Brody J, Prathuangsuk P et al. Immunosuppressive effects of erythropoietin on human alloreactive T cells. J Am Soc Nephrol 2014; 25: 2003-2015.
28. Wiedenmann T, Ehrhardt S, Cerny D, Hildebrand D, Klein S, Heeg K et al. Erythropoietin acts as an anti-inflammatory signal on murine mast cells. Mol Immunol 2015; 65: 68-76.
29. Luo B, Gan W, Liu Z, Shen Z, Wang J, Shi R et al. Erythropoeitin Signaling in Macrophages Promotes Dying Cell Clearance and Immune Tolerance. Immunity 2016; 44: 287-302.
30. Luo B, Wang J, Liu Z, Shen Z, Shi R, Liu YQ et al. Phagocyte respiratory burst activates macrophage erythropoietin signalling to promote acute inflammation resolution. Nat Commun 2016; 7: 12177.
31. Linkermann A, Green DR. Necroptosis. N Engl J Med 2014; 370: 455-465.
32. Linkermann A, Chen G, Dong G, Kunzendorf U, Krautwald S, Dong Z. Regulated cell death in AKI. J Am Soc Nephrol 2014; 25: 2689-2701.
33. Wang S, Zhang C, Hu L, Yang C. Necroptosis in acute kidney injury: a shedding light. Cell Death Dis 2016; 7: e2125.
34. Wang Z, Shah SV, Liu H, Baliga R. Inhibition of cytochrome P450 2E1 and activation of transcription factor Nrf2 are renoprotective in myoglobinuric acute kidney injury. Kidney Int 2014; 86: 338-349.
35. He S, Huang S, Shen Z. Biomarkers for the detection of necroptosis. Cell Mol Life Sci 2016; 73: 2177-2181.
36. Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol 2014; 32: 659-702.
37. Luo B, Jiang M, Yang X, Zhang Z, Xiong J, Schluesener HJ et al. Erythropoietin is a hypoxia inducible factor-induced protective molecule in experimental autoimmune neuritis. Biochim Biophys Acta 2013; 1832: 1260-1270.
38. Lee TS, Lu KY, Yu YB, Lee HT. Beta common receptor mediates erythropoietin-conferred protection on OxLDL-induced lipid accumulation and inflammation in macrophages. Mediators of Inflammation 2015; 2015: 1-13.
39. Wood MA, Goldman N, DePierri K, Somerville J, Riggs JE. Erythropoietin increases macrophage-mediated T cell suppression. Nat Commun 2016; 306-307: 17-24.
40. Alnaeeli M, Raaka BM, Gavrilova O, Teng R, Chanturiya T, Noguchi CT. Erythropoietin signaling: a novel regulator of white adipose tissue inflammation during diet-induced obesity. Diabetes 2014; 63: 2415-2431.
41. Joshi D, Abraham D, Shiwen X, Baker D, Tsui J. Potential role oferythropoietin receptors and ligands in attenuating apoptosis and inflammation in critical limb ischemia. J Vasc Surg 2014; 60: 191-201 201.e1-2.
42. Liu Y, Luo B, Han F, Li X, Xiong J, Jiang M et al. Erythropoietin-derived nonerythropoietic peptide ameliorates experimental autoimmune neuritis by inflammation suppression and tissue protection. PLoS ONE 2014; 9: e90942.
43. Liu Y, Luo B, Shi R, Wang J, Liu Z, Liu W et al. Nonerythropoietic Erythropoietin-derived peptide suppresses adipogenesis, inflammation, obesity and insulin resistance. Sci Rep 2015; 5: 15134.
44. Watanabe M, Lundgren T, Saito Y, Cerami A, Brines M, Ostenson CG et al. A nonhematopoietic erythropoietin analogue, ARA 290, inhibits macrophage activation and prevents damage to transplanted islets. Transplantation 2016; 100: 554-562.
45. Lifshitz L, Tabak G, Gassmann M, Mittelman M, Neumann D. Macrophages as novel target cells for erythropoietin. Haematologica 2010; 95: 1823-1831.
46. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677-686.
47. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8: 958-969.
48. Rees AJ Monocyte and macrophage biology: an overview. Semin Nephrol 2010; 30: 216-233.
49. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012; 122: 787-795.
50. Duffield JS Macrophages and immunologic inflammation of the kidney. Semin Nephrol 2010; 30: 234-254.
51. Kawakami T, Lichtnekert J, Thompson LJ, Karna P, Bouabe H, Hohl TM et al. Resident renal mononuclear phagocytes comprise five discrete populations with distinct phenotypes and functions. J Immunol 2013; 191: 3358-3372.
52. Stamatiades EG, Tremblay ME, Bohm M, Crozet L, Bisht K, Kao D et al. Immune monitoring of trans-endothelial transport by kidney-resident macrophages. Cell 2016; 166: 991-1003.
53. Jang HR, Rabb H. Immune cells in experimental acute kidney injury. Nat Rev Nephrol 2015; 11: 88-101.
54. Williams TM, Little MH, Ricardo SD. Macrophages in renal development, injury, and repair. Semin Nephrol 2010; 30: 255-267.
55. Alikhan MA, Jones CV, Williams TM, Beckhouse AG, Fletcher AL, Kett MM et al. Colony-stimulating factor-1 promotes kidney growth and repair via alteration of macrophage responses. Am J Pathol 2011; 179: 1243-1256.
56. Zhang MZ, Yao B, Yang S, Jiang L, Wang S, Fan X et al. CSF-1 signaling mediates recovery from acute kidney injury. J Clin Invest 2012; 122: 4519-4532.
57. Huen SC, Huynh L, Marlier A, Lee Y, Moeckel GW, Cantley LG. GM-CSF Promotes Macrophage Alternative Activation after Renal Ischemia/Reperfusion Injury. J Am Soc Nephrol 2015; 26: 1334-1345.
58. Wang Y, Chang J, Yao B, Niu A, Kelly E, Breeggemann MC et al. Proximal tubule-derived colony stimulating factor-1 mediates polarization of renal macrophages and dendritic cells, and recovery in acute kidney injury. Kidney Int 2015; 88: 1274-1282.
59. Chiba T, Skrypnyk NI, Skvarca LB, Penchev R, Zhang KX, Rochon ER et al. Retinoic Acid Signaling Coordinates Macrophage-Dependent Injury and Repair after AKI. J Am Soc Nephrol 2016; 27: 495-508.
60. Wang Y, Wang YP, Zheng G, Lee VW, Ouyang L, Chang DH et al. Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. Kidney Int 2007; 72: 290-299.
61. Ko GJ, Boo CS, Jo SK, Cho WY, Kim HK. Macrophages contribute to the development of renal fibrosis following ischaemia/reperfusion-induced acute kidney injury. Nephrol Dial Transplant 2008; 23: 842-852.
62. Vernon MA, Mylonas KJ, Hughes J. Macrophages and renal fibrosis. Semin Nephrol 2010; 30: 302-317.